GeneDx Holdings Corp. (WGS)
| Market Cap | 2.06B -40.8% |
| Revenue (ttm) | 454.43M +25.4% |
| Net Income | -106.36M |
| EPS | -3.64 |
| Shares Out | 29.82M |
| PE Ratio | n/a |
| Forward PE | 104.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 832,725 |
| Open | 69.16 |
| Previous Close | 68.74 |
| Day's Range | 68.25 - 71.53 |
| 52-Week Range | 32.21 - 170.87 |
| Beta | 1.97 |
| Analysts | Strong Buy |
| Price Target | 93.50 (+35.63%) |
| Est. Earnings | Nov 3, 2026 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Financial Performance
In 2025, GeneDx Holdings's revenue was $427.54 million, an increase of 39.97% compared to the previous year's $305.45 million. Losses were -$21.02 million, -59.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $93.5, which is an increase of 35.63% from the latest price.
News
GeneDx enhances genome testing portfolio with long-read whole-genome sequencing
The company states: “GeneDx (WGS) announced plans to enhance its genome testing portfolio with long-read whole genome sequencing. Long-read sequencing analyzes longer stretches of DNA to identify comp...
GeneDx announces plans to enhance genome testing portfolio with lrWGS
GeneDx (WGS) announced plans to enhance its genome testing portfolio with long-read whole genome sequencing, lrWGS. Leveraging insights from GeneDx Infinity and decades of clinical interpretation, Gen...
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testi...
GeneDx advances clinical adoption of genomic medicine with 27 abstracts at ASHG
The company states: “GeneDx (WGS) announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are adva...
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the America...
GeneDx presents new findings on genomic newborn screening at ICoNS 2026
GeneDx (WGS) announced new findings to be presented at the International Consortium on Newborn Sequencing, ICoNS, October 7-8 in Boston, demonstrating progress toward making genomic newborn screening ...
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026.
GeneDx to introduce Easy Order at AAP 2026
GeneDx (WGS) announced it will introduce Easy Order at the 2026 American Academy of Pediatrics National Conference & Exhibition, October 2-6 in San Diego. The new streamlined experience makes it…
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.
GeneDx price target raised to $83 from $74 at Guggenheim
Guggenheim raised the firm’s price target on GeneDx (WGS) to $83 from $74 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for select…
GeneDx selloff after CMS news ‘probably too extreme,’ says Craig-Hallum
Craig-Hallum notes that GeneDx (WGS) is down over 9% on uncertainty surrounding the potential impact from proposed exome and genome rate cuts included in the Centers for Medicare and Medicaid…
GeneDx, Beren Therapeutics launch NPC GenomeComplete
GeneDx (WGS) announced a collaboration with Beren Therapeutics to launch the NPC GenomeComplete Sponsored Testing Program. The program provides no-cost genome sequencing for eligible pediatric patient...
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
GeneDx Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong Q2 growth was driven by core channels, with significant untapped potential remaining in geneticists, pediatric neurology, and NICU. Expansion into primary care and prenatal markets is underway, supported by new guidelines and operational improvements. Collection rates and gross margins are expected to rise as automation and payer-specific processes are implemented.
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
GeneDx announces data published in Genetics in Medicine on genome sequencing
GeneDx (WGS) announced new data published in Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics, ACMG, in collaboration with the clinical genetics team…
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
GeneDx Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference
Second quarter saw 32% volume growth and a return to adjusted profitability, driven by expanded policy coverage for whole genome sequencing. Efforts focus on improving collection rates, optimizing product mix, and leveraging new guidelines and commercial expansion to drive future revenue growth.
GeneDx launches new online offering to expand accessibility of exome testing
GeneDx (WGS) announced the launch of a new online offering designed to expand accessibility of exome testing across the U.S. at scale for pediatric patients with global developmental delay, GDD,…
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.
GeneDx price target raised to $90 from $75 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on GeneDx (WGS) to $90 from $75 and keeps a Buy rating on the shares. The firm said its target increase…
GeneDx Holdings Earnings Call Transcript: Q2 2026
Record Q2 volume and revenue exceeded guidance, with profitability achieved ahead of schedule. Strong demand and expanded payer coverage, especially for genome testing, set the stage for sustained growth, with significant improvements in collection rates and cash flow expected in late 2026 and 2027.
GeneDx Holdings Slides: Q2 2026
GeneDx Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.